What is the likely cause of the troponin elevation in this patient with complete heart block, syncope, low cardiac output, elevated B-type natriuretic peptide (BNP), and metoprolol therapy?

Likely Cause: Acute Myocardial Injury from Complete Heart Block and Low Cardiac Output

The troponin elevation in this patient is most likely due to acute myocardial injury secondary to complete heart block causing severe bradycardia, syncope, and low cardiac output—not acute coronary syndrome from plaque rupture. 1

Understanding the Clinical Context

This patient presents with a constellation of findings that point away from acute coronary syndrome (ACS):

• Complete heart block causing severe bradycardia
• Syncope from inadequate cerebral perfusion
• Low cardiac output state
• Elevated BNP indicating hemodynamic stress
• Metoprolol therapy potentially exacerbating bradycardia

Why This Matters for Troponin Interpretation

Troponin elevation does not automatically equal myocardial infarction. 1 The 2014 AHA/ACC guidelines explicitly state that "solitary elevations of troponin cannot be assumed to be due to MI, because troponin elevations can be due to tachyarrhythmia, hypotension or hypertension, cardiac trauma, acute HF, myocarditis and pericarditis, acute pulmonary thromboembolic disease" 1. In this case, the complete heart block with resultant severe bradycardia and low cardiac output creates a supply-demand mismatch causing myocardial injury.

Pathophysiologic Mechanism

The complete heart block leads to:

1. Severe bradycardia (likely ventricular escape rhythm at 30-40 bpm)
2. Reduced cardiac output and coronary perfusion pressure
3. Myocardial oxygen supply-demand mismatch even without coronary occlusion
4. Cardiomyocyte necrosis releasing troponin into circulation

The elevated BNP further supports hemodynamic compromise and ventricular strain 2, 3. Recent meta-analysis data show that combined elevation of BNP and troponin in syncope patients indicates particularly high risk, with BNP demonstrating 80% sensitivity for identifying cardiac syncope 2.

Critical Drug Interaction

Metoprolol is directly contributing to this patient's presentation. 4 The FDA label explicitly warns that "bradycardia, including sinus pause, heart block, and cardiac arrest have occurred with the use of metoprolol. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may be at increased risk" 4.

In the setting of complete heart block, metoprolol:

• Suppresses escape rhythms
• Reduces cardiac output further through negative inotropic effects
• Worsens the supply-demand mismatch causing troponin elevation

Metoprolol must be immediately discontinued 4.

Distinguishing from Type 1 MI

To diagnose acute MI (Type 1), you need 1:

• Rising/falling troponin pattern (not just elevation)
• Clinical evidence of myocardial ischemia (chest pain, ischemic ECG changes)
• Typically occurs in context of acute plaque rupture

This patient's presentation lacks:

• Ischemic chest pain
• ST-segment changes suggesting acute coronary occlusion
• The clinical context suggests hemodynamic cause rather than thrombotic

Type 2 MI Consideration

This could represent Type 2 MI (supply-demand mismatch) if there is underlying coronary disease, but the primary driver is the complete heart block causing inadequate coronary perfusion, not acute plaque rupture 5.

Immediate Management Priorities

1. Stop metoprolol immediately 4
2. Prepare for temporary pacing - complete heart block with syncope and low output requires urgent pacing
3. Do NOT treat with antithrombotic/antiplatelet therapy beyond standard indications 6 - this is not ACS from plaque rupture
4. Address the conduction abnormality as the root cause
5. Consider permanent pacemaker once stabilized

Common Pitfall to Avoid

Do not reflexively treat elevated troponin as ACS requiring dual antiplatelet therapy and anticoagulation. 6, 7 The 2023 CHEST guidelines on COVID-19 (applicable principle here) explicitly recommend against DAPT for isolated myocardial injury without ACS 6. This principle applies broadly: troponin elevation from non-thrombotic causes should not trigger antithrombotic therapy, which only increases bleeding risk without benefit 7.

Prognostic Implications

The combination of elevated troponin and BNP in this hemodynamic context carries significant prognostic weight 3. Studies show that patients with both BNP ≥840 pg/mL and elevated troponin have 10.2% in-hospital mortality versus 2.2% with neither elevated 3. However, correcting the underlying complete heart block with pacing should improve both the hemodynamics and the troponin elevation 8.